XML 35 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
REVENUES    
Total revenues $ 4,983,556 $ 5,653,725
EXPENSES    
Cost of product sales 4,302,755 4,332,485
General and administrative 10,835,647 11,724,964
Research and development 6,837,133 11,716,718
Sales and marketing 950,420 542,594
Goodwill and fixed asset impairment 4,239,000
Total expenses 27,164,955 28,316,761
LOSS FROM OPERATIONS (22,181,399) (22,663,036)
OTHER EXPENSE (INCOME), NET    
Gain on change in fair value of warrant liabilities (907,203) (4,723,187)
Interest (income) expense, net 26,646 (42,693)
Other income, net (1,125) (5,446)
Total other expense (income), net (881,682) (4,771,326)
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES (21,299,717) (17,891,710)
(BENEFIT) PROVISION FOR INCOME TAXES (265,074) 5,427
Net loss (21,034,643) (17,897,137)
Net loss attributable to noncontrolling interest (2,394,100)
Net loss attributable to Qualigen Therapeutics, Inc. $ (18,640,543) $ (17,897,137)
Net loss per common share, basic and diluted $ (4.85) $ (6.10)
Weighted—average number of shares outstanding, basic and diluted 3,840,340 2,933,487
Other comprehensive loss, net of tax    
Foreign currency translation adjustment $ 50,721
Other comprehensive loss (20,983,922) (17,897,137)
Comprehensive loss attributable to noncontrolling interest (2,394,100)
Comprehensive loss attributable to Qualigen Therapeutics, Inc. (18,589,822) (17,897,137)
Net Product Sales [Member]    
REVENUES    
Total revenues 4,983,556 5,021,721
License Revenue [Member]    
REVENUES    
Total revenues $ 632,004